1Framingham Risk Score — Clinical Guide
The Framingham Risk Score was developed from the Framingham Heart Study, a landmark prospective cohort study initiated in 1948 in Framingham, Massachusetts. The 1998 Wilson et al. equations (JAMA) use age, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive treatment, smoking, and diabetes to predict 10-year risk of coronary heart disease events (MI, coronary death, unstable angina, coronary insufficiency) in adults aged 30–79 without existing CHD.
Risk Categories
- Low (<10%): Lifestyle counselling. Statin not routinely indicated unless LDL ≥190 mg/dL
- Intermediate (10–19%): Consider statin; individualise based on risk factors and patient preference
- High (≥20%): Statin therapy recommended — high-intensity preferred (atorvastatin 40–80 mg or rosuvastatin 20–40 mg)
Framingham vs ASCVD — Key Differences
- Framingham predicts CHD events only; ASCVD (Pooled Cohort Equations) predicts both MI and stroke — broader endpoint
- Framingham is validated for ages 30–79; ASCVD for 40–79
- Both validated primarily in White populations; apply with caution in South Asian and other populations
- For South Asian patients (including Indian subcontinent), multiply risk by 1.4–1.5 to account for higher intrinsic risk
Lifestyle Risk Reduction — Evidence-Based
- Smoking cessation: reduces CHD risk by 50% within 1 year — most impactful single intervention
- Diet: Mediterranean or DASH diet — reduces LDL by 10–15%, lowers BP, reduces inflammation
- Physical activity: 150 min/week moderate aerobic exercise — reduces CHD risk by 30–35%
- BP control to <130/80 mmHg: each 10 mmHg SBP reduction reduces CHD risk by 25%
- Diabetes control: HbA1c <7% — reduces microvascular risk; SGLT2 inhibitors reduce MACE in T2DM
2Frequently asked questions
What does the Framingham Risk Score calculate?
The Framingham Risk Score estimates the 10-year risk of a first major cardiovascular event (myocardial infarction, coronary death, or angina) based on age, sex, total cholesterol, HDL cholesterol, systolic BP, BP treatment status, diabetes, and smoking. It was derived from the Framingham Heart Study cohort and is one of the oldest validated CVD risk tools.
How is Framingham risk classified?
10-year CVD risk: Low: <10%. Intermediate: 10–20%. High: >20%. Patients with established CVD or diabetes are automatically high risk. High-risk patients benefit from statin therapy, BP control to <130/80 mmHg, and antiplatelet therapy (if established CVD). Intermediate-risk patients require individualised decisions.
Does Framingham risk apply to Indian patients?
The Framingham equations were derived from predominantly White American populations and overestimate risk in some ethnic groups while underestimating in South Asians. Indians develop CVD at younger ages and at lower risk factor levels. The INTERHEART study showed South Asians have higher population-attributable risk from abdominal obesity and diabetes. Use Framingham as a starting point but apply clinical judgment for Indian patients.
What modifies Framingham risk score?
Risk-enhancing factors that increase effective risk beyond calculated score: family history of premature ASCVD (men <55, women <65), high-sensitivity CRP ≥2 mg/L, lipoprotein(a) ≥50 mg/dL, ABI <0.9, metabolic syndrome, chronic inflammatory conditions (RA, psoriasis, HIV), and chronic kidney disease. These factors support earlier or more intensive statin therapy in intermediate-risk patients.
What lifestyle changes reduce cardiovascular risk?
Smoking cessation (most impactful — halves CV risk within 1 year), Mediterranean/DASH diet, aerobic exercise (150 min/week moderate intensity), weight loss (5–10% reduces multiple risk factors), optimal BP control (<130/80 mmHg), and glycaemic control in diabetes (HbA1c <7%). Combined, these reduce 10-year Framingham risk by 30–50%.
When should a statin be started based on Framingham risk?
High risk (>20%): high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg). Intermediate risk (10-20%): moderate-to-high intensity statin recommended. Low-intermediate (7.5-10%): statin should be considered, especially with risk-enhancing factors. Low risk (<7.5%): lifestyle modification first; statin if LDL remains ≥160 mg/dL. Always combine with lifestyle intervention.
Medical disclaimer: This calculator is for educational and clinical decision-support purposes only. It does not replace clinical judgment or specialist consultation. RxMedCalc is not liable for clinical decisions made solely on this tool.